[HTML][HTML] Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation
L Gao, J Schwartzman, A Gibbs, R Lisac… - PloS one, 2013 - journals.plos.org
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
L Gao, J Schwartzman, A Gibbs, R Lisac… - PLoS ONE, 2013 - go.gale.com
Prostate cancer is the most common cancer in men in the United States with 241,740 new
cases anticipated this year [1]. Despite screening and early treatment, prostate cancer …
cases anticipated this year [1]. Despite screening and early treatment, prostate cancer …
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.
L Gao, J Schwartzman, A Gibbs, R Lisac… - Plos one, 2013 - europepmc.org
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
[引用][C] Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
L Gao, J Schwartzman, A Gibbs, R Lisac… - PLoS …, 2013 - ui.adsabs.harvard.edu
Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc
Upregulation - NASA/ADS Now on home page ads icon ads Enable full ADS view NASA/ADS …
Upregulation - NASA/ADS Now on home page ads icon ads Enable full ADS view NASA/ADS …
[PDF][PDF] Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression
L Gao, J Schwartzman, A Gibbs, R Lisac… - 2013 - researchgate.net
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
[PDF][PDF] Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression
L Gao, J Schwartzman, A Gibbs, R Lisac… - 2013 - academia.edu
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
[PDF][PDF] Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression
L Gao, J Schwartzman, A Gibbs, R Lisac… - 2013 - Citeseer
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
[PDF][PDF] Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression
L Gao, J Schwartzman, A Gibbs, R Lisac… - 2013 - cyberleninka.org
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
L Gao, J Schwartzman, A Gibbs, R Lisac… - PLoS …, 2013 - search.ebscohost.com
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
[HTML][HTML] Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
L Gao, J Schwartzman, A Gibbs, R Lisac… - PLoS ONE, 2013 - ncbi.nlm.nih.gov
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …